ADMS
Adamas Pharmaceuticals, Inc.
Set alert
8.22 0.00 0.00%
8.18 Day range 8.25
52-week range unavailable
- Open
- 8.24
- Prev close
- 8.22
- Mkt cap
- 376.37M
- Vol
- 3.15M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.18
- High
- 8.25
- Forward P/E
- -22.22
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2021
- 50-d avg
- 7.00
- 200-d avg
- 5.54
- 1y target
- 8.52
Key statistics
- Market cap
- 376.37M
- Trailing P/E
- 0.00
- Forward P/E
- -22.22
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 7.00
- 200-day average
- 5.54
Analyst view
Consensus: hold
Hold
Price target (mean) 8.52 +3.6% upside
Now 8.22
- Target (low)
- 8.00
- Target (mean)
- 8.52
- Target (high)
- 9.10
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy1
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2021
Expected Nov 10, 2021. Consensus EPS estimate -0.18.
Financials — quick view
ADMS Revenue — quarterly 25.90M
ADMS Net income — quarterly -19.52M
ADMS EPS — quarterly -0.43
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2021 | Sep 1, 2021 | -0.22 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | -0.27 | — | — | — |
| May 10, 2021 | Mar 1, 2021 | -0.48 | — | — | — |
| Feb 23, 2021 | Dec 1, 2020 | -0.53 | — | — | — |
| Nov 5, 2020 | Sep 1, 2020 | -0.50 | — | — | — |
| Aug 6, 2020 | Jun 1, 2020 | -0.61 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2021 | JMP Securities | down | Market Outperform | Market Perform |
| Oct 12, 2021 | Piper Sandler | down | Overweight | Neutral |
| Oct 12, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 11, 2021 | William Blair | down | Outperform | Market Perform |
| Jun 7, 2021 | HC Wainwright & Co. | main | — | Buy |
| Dec 17, 2019 | Cantor Fitzgerald | reit | — | Neutral |
News
- Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Adamas Pharmaceuticals, Inc. (ADMS) Settlement Fund Before Deadline
- $4,650,000 Recovery from Adamas Pharmaceuticals, Inc. (ADMS). L&K, LLP Reminds Shareholders to File a Claim Before Deadline
- Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details
- Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details
- Levi & Korsinsky, LLP Announces $4,650,000 Recovery for Adamas Pharmaceuticals, Inc. (ADMS). File Your Claim Before Deadline
- Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery
- Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery
- Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement
- Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement
Your note
Sign in to keep a note on ADMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIGHAM MICHAEL F | Director | Stock Award(Grant) | Jun 1, 2021 | 10,000 |
| DEMSKI MARTHA J. | Director | Sale | Jun 6, 2021 | 21,000 |
| DIER MARDI C | Director | Stock Award(Grant) | Jun 1, 2021 | 10,000 |
| ERICSON WILLIAM W | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 1, 2021 | 4,629,800 |
| MACPHEE JOHN A | Director | Stock Award(Grant) | Jun 1, 2021 | 202,000 |
| MAHONEY DAVID L | Director | Stock Award(Grant) | Jun 1, 2021 | 117,781 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.90% | 5,449,340 | 26.76M | Sep 29, 2021 |
| Armistice Capital, LLC | 8.74% | 4,000,000 | 19.64M | Sep 29, 2021 |
| Stonepine Capital Management, LLC | 8.55% | 3,914,938 | 19.22M | Sep 29, 2021 |
| AIGH Capital Management LLC | 5.65% | 2,585,743 | 12.70M | Sep 29, 2021 |
| Vanguard Group, Inc. (The) | 3.85% | 1,765,031 | 8.67M | Sep 29, 2021 |
| Opaleye Management Inc. | 3.19% | 1,460,000 | 7.17M | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Variable Insurance Products Fund-Growth Portfolio | 4.14% | 1,895,400 | 9.31M | Sep 29, 2021 |
| Fidelity Capital Appreciation Fund | 3.20% | 1,466,500 | 7.20M | Sep 29, 2021 |
| Vanguard Total Stock Market Index Fund | 2.41% | 1,105,504 | 5.84M | Jun 29, 2021 |
| Fidelity Advisor Equity Growth Fund | 2.32% | 1,064,200 | 5.23M | Sep 29, 2021 |
| Fidelity Growth Discovery Fund | 1.58% | 722,700 | 3.55M | Sep 29, 2021 |
| Vanguard Extended Market Index Fund | 1.25% | 573,050 | 3.03M | Jun 29, 2021 |